Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adult T-cell leukaemia/lymphoma with different histological features in a single lymph node.

Journal of clinical and experimental hematopathology : JCEH·2026
Same author

Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027).

PloS one·2026
Same author

High bilirubin and blood urea nitrogen predict intestinal necrosis in incarcerated groin hernia.

Hernia : the journal of hernias and abdominal wall surgery·2026
Same author

Novel Closure Technique With Double-Balloon Endoscopy-Guided Embolization by Gelatin Sponge and Clip Suturing for Postoperative Enterocutaneous Fistula With Bile Leakage.

DEN open·2026
Same author

[A Case of Pancreatic Acinar Cell Carcinoma Undergoing Two Hepatic Resections for Metachronous Liver Metastases].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same author

[A Resected Case of Leiomyosarcoma of the Transverse Mesocolon with Difficult Preoperative Diagnosis].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Related Experiment Video

Updated: Jun 7, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Endoglin-targeted cancer therapy.

Ben K Seon1, Akinao Haba, Fumihiko Matsuno

  • 1Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. ben.seon@roswellpark.org

Current Drug Delivery
|November 2, 2010
PubMed
Summary
This summary is machine-generated.

Endoglin (ENG) is a promising target for vascular-targeting antiangiogenic therapy (VTAT) in cancer. Anti-ENG monoclonal antibodies (mAbs) demonstrated efficacy in suppressing tumor growth, metastasis, and angiogenesis in preclinical models.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jun 7, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Immunology
  • Vascular Biology

Background:

  • Vascular-targeting antiangiogenic therapy (VTAT) offers potential advantages over conventional cancer therapies.
  • Endoglin (ENG; CD105) is selectively expressed on tumor vasculature and lymphatic endothelium, making it an attractive target.
  • ENG plays a crucial role in angiogenesis and vascular development.

Purpose of the Study:

  • To evaluate endoglin (ENG) as a target for VTAT.
  • To assess the efficacy of anti-ENG monoclonal antibodies (mAbs) in preclinical cancer models.
  • To investigate the safety and immunogenicity of a chimeric anti-ENG mAb (c-SN6j) for clinical application.

Main Methods:

  • Studies utilized animal models and in vitro assays with anti-ENG mAbs and their immunoconjugates.
  • Pharmacokinetics, toxicology, and immunogenicity of c-SN6j were assessed in nonhuman primates.
  • A Phase 1 clinical trial (NCT00582985) of c-SN6j (TRC105) in cancer patients is ongoing.

Main Results:

  • Anti-ENG mAbs and immunoconjugates induced tumor regression, inhibited new tumor formation, and suppressed metastasis.
  • Mechanisms of action included direct endothelial cell growth suppression, apoptosis induction, ADCC, and T cell immunity.
  • c-SN6j exhibited no significant toxicity and minimal immunogenicity in nonhuman primates.

Conclusions:

  • Endoglin (ENG) is a validated target for VTAT in cancer.
  • Anti-ENG mAbs, including the chimeric c-SN6j, show significant preclinical efficacy and a favorable safety profile.
  • Clinical trials are underway to confirm the therapeutic potential of c-SN6j in cancer patients.